Quantification of m6A RNA methylation modulators pattern was a potential biomarker for prognosis and associated with tumor immune microenvironment of pancreatic adenocarcinoma

Table 2 Demographic and clinicopathological parameters of PAAD patients based on TCGA datasets

Clinical characteristics	All	High m6Ascore	low m6Ascore	P value
Age	64.54 ± 10.81	63.74 ± 11.68	65.33 ± 9.88	0.387
Gender				0.735
Female	66	34	32
Male	74	36	38
Race				0.689
Asian	8	5	3
White	123	60	63
Black or African American	5	2	3
Fustat				< 0.001
Living	63	21	42
Deceased	77	49	28
Pathologic stage				0.927
I (IA + IB)	12	6	6
II (IIA + IIB)	121	60	61
III+ IV	7	4	3
T				0.813
T1+ T2	21	10	11
T3 + T4	119	60	59
M				0.361
M0	66	34	32
M1	4	3	1
N				0.808
N0	37	19	18
N1(N1a + N1b)	102	50	52
Histologic grade				0.140
G1-G2	98	45	53
G3-G4	42	25	17
Site
Head of pancreas	110	54	56	0.139
Body of pancreas	11	8	3
Tail of pancreas	10	6	4
others	9	2	7
Maximum tumor dimension	3.75 ± 1.44	4.05 ± 1.72	3.42 ± 0.98	0.013
History of targeted molecular therapy				0.185
YES	75	37	38
NO	35	22	13
Alcohol drinking history				0.910
YES	80	40	40
NO	49	24	25
History of chronic pancreatitis				0.726
YES	12	7	5
NO	100	53	47
History of diabetes				0.157
YES	32	13	19
NO	85	47	38
Family history of cancer				0.910
YES	50	21	29
NO	33	23	10

ISSN: 1471-2407